The Dianthus stock rating from Roth Capital began with a Buy recommendation and a $113 price target on October 15, 2023. The historical rating’s current status is not established.
Key Takeaways
- Roth Capital initiated coverage with a Buy rating and a $113 target.
- A quoted share price of $79.33 has no stated observation date.
Dianthus stock rating and price target
Roth Capital’s initiation covered Dianthus Therapeutics, which trades under the ticker DNTH. A Buy rating expresses an analyst’s recommendation; the $113 target is an estimate, not a guaranteed future share price.
The accompanying market snapshot listed the stock at $79.33. Because no observation date was specified for that price, it should not be assumed to reflect trading on the rating date or the latest market price.
Clinical-stage drug development
Dianthus is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases. Its lead candidate, claseprubart, also known as DNTH103, targets multiple autoimmune and neuromuscular indications.
The accompanying company snapshot described Dianthus as having no approved products or generated revenue and relying on equity financing. The date of that financial snapshot was not specified.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
Comments
Be respectful. No spam, impersonation or private credentials. Ordinary posts and comments appear immediately; suspicious links are held for review.
Please wait…